BET Bromodomain Inhibitors Synergize With ATR Inhibitors in Melanoma in Melanoma

Cell Death and Disease - United Kingdom
doi 10.1038/cddis.2017.383
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Inhibitors of Pan-Pi3k Signaling Synergize With BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth

Frontiers in Oncology
Cancer ResearchOncology
2015English

Rechallenge With Checkpoint Inhibitors in Metastatic Melanoma

JDDG - Journal of the German Society of Dermatology
Dermatology
2020English

BET Bromodomain Inhibitors With One-Step Synthesis Discovered From Virtual Screen

Journal of Medicinal Chemistry
Drug DiscoveryMolecular Medicine
2017English

Recurrent Pneumonitis in Patients With Melanoma Treated With Immune Checkpoint Inhibitors

Oncologist
Cancer ResearchMedicineOncology
2019English

Resistance Mechanisms in Melanoma to Immuneoncologic Therapy With Checkpoint Inhibitors

2019English

Immune Checkpoint Inhibitors in Melanoma: Review and Update

Journal of the Portuguese Society of Dermatology and Venereology
2018English

AurkA Inhibitors Enhance the Effects of B-Raf and MEK Inhibitors in Melanoma Treatment

Journal of Translational Medicine
BiochemistryMedicineGeneticsMolecular Biology
2015English

Combining BET and HDAC Inhibitors Synergistically Induces Apoptosis of Melanoma and Suppresses AKT and YAP Signaling

Oncotarget
Oncology
2015English

Targeting the IGF1R/PI3K/AKT Pathway Sensitizes Ewing Sarcoma to BET Bromodomain Inhibitors

Molecular Cancer Therapeutics
Cancer ResearchOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy